Biopharmaceuticals
Regulatory
News Release - December 4, 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Source: Samsung Bioepis
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.